Toll Free: 1-888-928-9744
Published: May, 2014 | Pages:
45 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Protalix BioTherapeutics, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Protalix BioTherapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the Protalix BioTherapeutics, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Protalix BioTherapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Protalix BioTherapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Protalix BioTherapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Protalix BioTherapeutics, Inc.'s pipeline products Reasons to buy - Evaluate Protalix BioTherapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Protalix BioTherapeutics, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Protalix BioTherapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Protalix BioTherapeutics, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Protalix BioTherapeutics, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Protalix BioTherapeutics, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Protalix BioTherapeutics, Inc. Snapshot 5 Protalix BioTherapeutics, Inc. Overview 5 Key Information 5 Key Facts 5 Protalix BioTherapeutics, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Protalix BioTherapeutics, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Protalix BioTherapeutics, Inc. - Pipeline Products Glance 11 Protalix BioTherapeutics, Inc. - Late Stage Pipeline Products 11 Pre-Registration Products/Combination Treatment Modalities 11 Protalix BioTherapeutics, Inc. - Clinical Stage Pipeline Products 12 Phase II Products/Combination Treatment Modalities 12 Phase I Products/Combination Treatment Modalities 13 Protalix BioTherapeutics, Inc. - Early Stage Pipeline Products 14 Preclinical Products/Combination Treatment Modalities 14 Discovery Products/Combination Treatment Modalities 15 Protalix BioTherapeutics, Inc. - Drug Profiles 16 taliglucerase alfa 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 PRX-112 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 PRX-102 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 etanercept biosimilar 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 PRX-105 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 PRX-107 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 PRX-110 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 PRX-111 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 PRX-113 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Protalix BioTherapeutics, Inc. - Pipeline Analysis 27 Protalix BioTherapeutics, Inc. - Pipeline Products by Target 27 Protalix BioTherapeutics, Inc. - Pipeline Products by Route of Administration 29 Protalix BioTherapeutics, Inc. - Pipeline Products by Molecule Type 30 Protalix BioTherapeutics, Inc. - Pipeline Products by Mechanism of Action 31 Protalix BioTherapeutics, Inc. - Recent Pipeline Updates 33 Protalix BioTherapeutics, Inc. - Dormant Projects 41 Protalix BioTherapeutics, Inc. - Discontinued Pipeline Products 42 Discontinued Pipeline Product Profiles 42 PRX-111 42 taliglucerase alfa 42 Protalix BioTherapeutics, Inc. - Locations And Subsidiaries 43 Head Office 43 Appendix 44 Methodology 44 Coverage 44 Secondary Research 44 Primary Research 44 Expert Panel Validation 44 Contact Us 45 Disclaimer 45
List of Tables Protalix BioTherapeutics, Inc., Key Information 5 Protalix BioTherapeutics, Inc., Key Facts 5 Protalix BioTherapeutics, Inc. - Pipeline by Indication, 2014 8 Protalix BioTherapeutics, Inc. - Pipeline by Stage of Development, 2014 9 Protalix BioTherapeutics, Inc. - Monotherapy Products in Pipeline, 2014 10 Protalix BioTherapeutics, Inc. - Pre-Registration, 2014 11 Protalix BioTherapeutics, Inc. - Phase II, 2014 12 Protalix BioTherapeutics, Inc. - Phase I, 2014 13 Protalix BioTherapeutics, Inc. - Preclinical, 2014 14 Protalix BioTherapeutics, Inc. - Discovery, 2014 15 Protalix BioTherapeutics, Inc. - Pipeline by Target, 2014 28 Protalix BioTherapeutics, Inc. - Pipeline by Route of Administration, 2014 29 Protalix BioTherapeutics, Inc. - Pipeline by Molecule Type, 2014 30 Protalix BioTherapeutics, Inc. - Pipeline Products by Mechanism of Action, 2014 32 Protalix BioTherapeutics, Inc. - Recent Pipeline Updates, 2014 33 Protalix BioTherapeutics, Inc. - Dormant Developmental Projects,2014 41 Protalix BioTherapeutics, Inc. - Discontinued Pipeline Products, 2014 42
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.